Responses

Safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia: a systematic review and individual patient data meta-analysis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Robust medical research demands both reproducibility and generalizability to ensure that findings translate into effective clinical practice
    • Mohsen Salimi, General Practitioner Student Research Committee, Shiraz University of Medical Science, Shiraz, Iran

    This systematic review and individual patient data meta-analysis aimed to evaluate the safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia. The study's strengths include its comprehensive search strategy, thorough data extraction, and robust statistical analysis. However, several limitations and concerns arise from the study's methodology and results.

    Firstly, the study's generalizability is limited by its focus on South Asia, which may not be representative of other regions where P. vivax malaria is endemic. Additionally, the study only included patients with uncomplicated P. vivax malaria, which may not reflect the more severe cases often seen in clinical practice.

    Secondly, the study's inclusion criteria were quite restrictive, leading to the exclusion of 14 out of 32 identified studies due to lack of primaquine arm or incomplete data. This raises concerns about selection bias and the potential for missing important data.

    Thirdly, the study's definition of "low" and "high" total dose primaquine regimens seems arbitrary and may not be universally accepted. The categorization of daily doses into "low", "intermediate", and "high" also lacks clear justification.

    Fourthly, the study's haematological safety analysis was restricted to patients with ≥30% G6PD activity, which may not reflect the real-world scenario where patients wit...

    Show More
    Conflict of Interest:
    None declared.